Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

The research, funded by Parkinson's UK, reveals that an experimental drug, tasquinimod, originally developed for prostate cancer, may have the potential to treat Parkinson's disease.

Image taken by the team of Parkinson’s stem cell-derived neurons growing

The Oxford Parkinson's Disease Centre team, in a study led by Professor Richard Wade-Martins and Professor Caleb Webber, have found compelling evidence that an experimental cancer drug may have the potential to treat Parkinson's disease.

Their research, funded by Parkinson's UK, suggests that tasquinimod, a drug not yet on the market, works by interacting with a key protein inside brain cells called HDAC4. This interaction controls the activity of genes that may be critical in the development of Parkinson's. 

The team are using pioneering stem cell techniques to grow brain cells from skin cell samples, donated by both people with and without the condition.

 

More information is available on the Parkinson's UK website and the Parkinson's UK Research Blog

More detail is also available on The University of Oxford website.

Read the full Cell Stem Cell paper here.

Similar stories

Fellowship awarded to Mootaz Salman could pave the way for early intervention in Parkinson’s

Congratulations are in order for Departmental Research Lecturer Dr Mootaz Salman who has been awarded a prestigious Early Career Fellowship funded by the Leverhulme Trust.

Researchers discover novel form of adaptation in the auditory system

DPAG’s auditory neuroscience researchers have found that the auditory system adapts to the changing acoustics of reverberant environments by temporally shifting the inhibitory tuning of cortical neurons to remove reverberation.

Collaborative team driven by DPAG and Chemistry awarded RSC Horizon Prize

The Molecular Flow Sensor Team, with collaborating members principally from DPAG’s Robbins and Talbot groups and the Department of Chemistry, has been named the winner of the Royal Society of Chemistry’s (RSC) Analytical Division Horizon Prize for the development of a new technology for measuring lung function.

REF 2021 results

Oxford Parkinson’s Disease Centre awarded £3.8 million to reveal the role of calcium in Parkinson’s

A collaborative research team led by the Oxford Parkinson’s Disease Centre (OPDC) has been awarded a £3.8 million Wellcome Trust Collaborative Award to study the function of calcium in dopamine neurons, and how this is plays a role in Parkinson’s. Their research will help explain how and why dopamine neurons are vulnerable in the disease and look at how they may be preserved.